

Communication

Monomethylarsenite Competes with Zn for Binding Sites in the Glucocorticoid Receptor

Anne M. Spuches, and Dean E. Wilcox

J. Am. Chem. Soc., 2008, 130 (26), 8148-8149 • DOI: 10.1021/ja802179p • Publication Date (Web): 05 June 2008

Downloaded from http://pubs.acs.org on February 8, 2009



More About This Article

Additional resources and features associated with this article are available within the HTML version:

- Supporting Information
- Access to high resolution figures
- Links to articles and content related to this article
- Copyright permission to reproduce figures and/or text from this article

View the Full Text HTML





Published on Web 06/05/2008

Monomethylarsenite Competes with Zn²⁺ for Binding Sites in the Glucocorticoid Receptor

Anne M. Spuches[‡] and Dean E. Wilcox^{*}

Department of Chemistry, Dartmouth College, Hanover, New Hampshire 03755

Received March 24, 2008; E-mail: dwilcox@dartmouth.edu

Human diseases, including type II diabetes, cardiovascular disease, and cancer of the lung, skin, bladder, liver, and kidney, have been correlated with chronic exposure to arsenic,¹ primarily as arsenite (As(III)) in drinking water. The connection with such disparate diseases is somewhat puzzling, but there is growing evidence that arsenic affects pathways controlled by steroid hormones, thus behaving as an endocrine disruptor.² However, the molecular mechanism by which it disrupts hormone-regulated gene expression is not yet known.

Methylated arsenic species are found in the urine of individuals ingesting low levels of arsenic,³ and intracellular methyltransferases that catalyze the oxidative addition of up to three methyl groups to arsenic have been identified.⁴ Results from tissue culture⁵ and animal⁶ studies suggest that monomethylarsenite (MMA^{III}) is more toxic than arsenite, but methylation occurs within cells and this difference may relate to differential transport and uptake. We have shown, however, that MMA^{III} forms more stable complexes than arsenite with the biologically relevant thiol glutathione (GSH).⁷ Further, recent studies suggest that individual differences in arsenic methylation may correlate with differences in health risks.⁸

Cell culture assays have shown that arsenic modulates transcription that is regulated by the glucocorticoid receptor $(GR)^2$ and other members of the hormone receptor family.⁹ Systematic truncation of GR indicates that the conserved DNA-binding domain (DBD) is a likely target for arsenite.¹⁰ This ~80 residue domain requires two Zn²⁺ ions, each coordinated to four Cys residues, to stabilize a protein structure¹¹ that is competent to bind as a head-to-head dimer to the near palindromic DNA sequence of the glucocorticoid response element (GRE).¹² Since arsenite has a known affinity for thiols, it is possible that competition with Zn²⁺ for the DBD Cys residues may be a key molecular event in arsenic disruption of GR-regulated pathways. It has been shown that Au⁺, Cu⁺, and Cd²⁺ inhibit GR binding to GRE;¹³ however, these ions have a higher affinity than Zn²⁺ for thiolate coordination, and it is unclear whether arsenite can compete with Zn²⁺ at physiological concentrations.

We have quantified the affinity of GR-DBD¹⁴ for Zn²⁺, arsenite, and MMA^{III} with isothermal titration calorimetry (ITC),¹⁵ and Figure 1 shows representative thermograms. The expected 2:1 stoichiometry of Zn²⁺ has been confirmed by ITC previously.¹⁶ On the basis of the usual tristhiolate and bisthiolate coordination of arsenite and MMA^{III},¹⁷ respectively, and the 10 Cys residues of GR-DBD, higher As(III) stoichiometries were expected. For example, arsenite and MMA^{III} bind to the 20 Cys residues of metallothionein with stoichiometries of ~6:1 and ~10:1, respectively.¹⁸ Since both As(III) species also bind to GR-DBD with a 2:1 stoichiometry, the protein structure limits the domain to only two binding sites.

The best fit of Zn^{2+} binding isotherms requires two sites with different thermodynamics, which are evaluated in detail elsewhere.¹⁹

In the case of arsenite and MMA^{III}, however, both ions bind with indistinguishable fit parameters. Since ITC measures the overall solution equilibrium and Zn^{2+} has significantly different aqueous chemistry than that of As(III) species,¹⁷ it is necessary to evaluate the overall binding equilibrium in each case (eqs 1–3)²⁰ to obtain affinities and thermodynamics that can be compared (Supporting Information). Zn^{2+} has a quantifiable interaction with the buffer, which also becomes protonated when Zn^{2+} binds to the four Cys and displaces four protons. Arsenite and MMA^{III}, however, exist as hydroxo species in neutral aqueous solution, so there is negligible interaction with the buffer, and binding to Cys thiols leads to thiolate—As(III) coordination and formation of water.

$$2Zn(buff)_{x}^{2+}+GR-DBD+(8-2X)buff \rightleftharpoons$$

$$[Zn_2GR-DBD]^{4-} + 8buffH^+ \quad (1)$$

 $2As(OH)_3 + GR - DBD \rightleftharpoons [As_2GR - DBD] + 6H_2O$ (2)

$$2MeAs(OH)_2 + GR-DBD \rightleftharpoons [(MeAs)_2GR-DBD] + 4H_2O$$
 (3)

Analysis of the average best fit ITC values from ≥ 3 good data sets leads to buffer-independent stability constants for the two Zn²⁺ ions, which can be compared to those of As(OH)₃ and MeAs(OH)₂, binding to GR-DBD at pH 7.2 (Table 1).

The lower affinity for arsenite than MMA^{III} is consistent with previous results with small thiols.⁷ Comparison with Zn²⁺ reveals that the GR-DBD affinity for MMA^{III} is only an order of magnitude lower than its affinity for the less tightly bound Zn²⁺, allowing MMA^{III} to compete with one Zn²⁺ ion. Comparison of the binding thermodynamics at pH 7.2 (Table 1) reveals that Zn²⁺, particularly the first one, binds with less net enthalpy than arsenite and MMA^{III}, but the As(III) species have a significant entropic penalty.

Circular dichroism (CD) in the near-UV can be used to detect Zn^{2+} stabilization of GR-DBD secondary structure. However, neither arsenite nor MMA^{III} stabilize secondary structure, as indicated by CD spectral data (Supporting Information), even though they bind to GR-DBD with the same stoichiometry as Zn^{2+} . Therefore, arsenite and MMA^{III} competition with Zn^{2+} for GR-DBD has been monitored by CD under strictly anaerobic conditions (Figure 2). These data indicate that excess arsenite has no effect on the Zn-stabilized structure but that MMA^{III} causes a loss of secondary structure, consistent with partial or complete displacement of at least one Zn^{2+} ion and, therefore, loss of competence to bind to GRE.¹²

Finally, we consider other factors in a cellular competition between MMA^{III} and Zn^{2+} for GR-DBD, including the significant concentration of GSH that results in its complexes with As(III) and Zn^{2+} in intracellular equilibria (e.g., eq 4).²⁰

$$MeAs(GS)_2 + [Zn_2GR-DBD]^{4-} + 2H^{4-}$$

$$\rightleftharpoons$$
 [Zn(MeAs)GR-DBD]²⁻ + Zn(GS)₂ (4)



Figure 1. Representative ITC data for Zn²⁺ (left), arsenite (middle), MMA^{III} (right) titrations of 30, 40, and 45 µM GR-DBD, respectively; 25 °C, 0.10 M bis-Tris, pH 7.2; best fit values for Zn²⁺ (two-site model): $K_1 = 7 \pm 1 \times 10^6$, $\Delta H_1 = -33.3 \pm 0.2$ kcal/mol, $K_2 = (4.7 \pm 0.2) \times 10^5$, $\Delta H_2 = -46.9 \pm 0.1$ kcal/mol; arsenite (one-site model): n = 2.0, $K = (4.3 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$, $\Delta H = -19.0 \pm 0.1$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$ kcal/mol; MMA^{III} (one-site model): n = 2.0, $K = (1.6 \pm 0.1) \times 10^5$ kcal/mol; MMA^{III} (one-site model): n = 2.0, N = 0.0 kcal/mol; MMA^{III} (one-site model): n = 2.0, N = 0.0 kcal/mol; N = 0.0 $10^{6}, \Delta H = -16.5 \pm 0.1$ kcal/mol.



Figure 2. CD spectra of 30 µM Zn₂GR-DBD with increasing arsenite (left) and MMA^{III} (right); 37 °C, 25 mM phosphate, pH 7.2.

Table 1. Thermodynamics of Zn²⁺, Arsenite, and MMA^{III} Binding to GR-DBD at pH 7.2 and 25 °C

	Zn^{2+}	Zn ²⁺ 2	As(OH) ₃	MeAs(OH) ₂
log K	9 ± 2	7.5 ± 0.5	5.6 ± 0.6	6.2 ± 0.3
ΔG° (kcal/mol)	-12 ± 2	-10.2 ± 0.7	-7.6 ± 0.8	-8.5 ± 0.5
ΔH° (kcal/mol)	-5.7 ± 0.1	-13.0 ± 0.6	-20.3 ± 0.7	-16.5 ± 0.1
$\Delta S^{\circ} \; (\text{cal/mol} \boldsymbol{\cdot} \mathbf{K})$	22 ± 8	-9 ± 3	-43 ± 1	-27 ± 1

Using pH 7.2 stability constants determined in this study, the known stability constants for MeAs(GS)₂ $(1.3 \times 10^7)^7$ and Zn(GS)₂ $(3.9\times10^{13})^{21}$ and a reported value for the cellular concentration of free Zn²⁺ (0.4 fM),²² it can be estimated that \sim 0.5 μ M MMA^{III} is required for 50% formation of functionally compromised [Zn(MeAs)GR-DBD]²⁻ at pH 7.2. Since arsenic effects on GRregulated transcription are found in cells exposed to low micromolar levels of arsenite,^{9,10} it is quite plausible that this cellular concentration of MMA^{III} can be achieved.

Thus, thermodynamic and structural results indicate that MMA^{III}, but not arsenite, is able to compete with Zn²⁺ ions that are required to stabilize the functionally competent structure of the GR DNAbinding domain. Whether this is general for Cys₄ coordination sites remains to be determined, although a recent report suggests that this may be the case for the Cys₄ Zn-binding site in the DNA repair protein XPA.23

Acknowledgment. We are grateful to the Dartmouth Superfund Basic Research Program (NIH Grant 1-P42-ES007373) for support of this research. We thank Hilary Godwin for the GR-DBD vector and help with its expression and purification, and Joshua Hamilton and Jack Bodwell for their interest and help with the manuscript.

Supporting Information Available: Analysis of Zn²⁺ ITC data to remove buffer effects; CD spectra of GR-DBD species. This material is available free of charge via the Internet at http://pubs.acs.org.

References

- Abernathy, C. O.; Liu, Y. P.; Longfellow, D.; Aposhian, H. V.; Beck, B. D.; Fowler, B. A.; Goyer, R. A.; Menzer, R.; Rossman, T.; Thompson, C.; Waalkes, M. Environ. Health Perspect. 1999, 107, 593-597.
- Kaltreider, R. C.; Davis, A. M.; Latriviere, J. P.; Hamilton, J. W. Environ. Health Perspect. 2001, 109, 245–251.
 Le, X. C.; Lu, X.; Ma, M.; Cullen, W. R.; Aposhian, H. V.; Zheng, B. Anal. Chem. 2000, 72, 5172–5177.
- Zakharyan, R. A.; Wu, Y.; Bogdan, G. M.; Aposhian, H. V. Chem. Res. Toxicol. 1995, 8, 1029-1038
- Styblo, M.; Del Razo, L. M.; Vega, L.; Germolec, D. R.; LeCluyse, E. L.; Hamilton, G. A.; Reed, W.; Wang, C.; Cullen, W. R.; Thomas, D. J. Arch. *Toxicol.* **2000**, *74*, 289–299.
- (6) Petrick, J. S.; Bhumasamudram, J.; Mash, E. A.; Aposhian, H. V. Chem. Res. Toxicol. 2001, 14, 651–656.
- Spuches, A. M.; Kruszyna, H. G.; Rich, A. M.; Wilcox, D. E. Inorg. Chem. (7)2005, 44, 2964-2972.
- McCarty, K. M.; Chen, Y.-C.; Quamruzzaman, Q.; Rahman, M.; Mahiuddin, G.; Hseueh, Y-M.; Su, L.; Smith, T.; Ryan, L.; Christiani, D. C. Environ. Health Perspect. 2007, 115, 341-345.
- Bodwell, J. E.; Gosse, J. A.; Nomikos, A. P.; Hamilton, J. W. Chem. Res. *Toxicol.* **2006**. *19*. 1619–1629.
- (10) Bodwell, J. E.; Kingsley, L. A.; Hamilton, J. W. Chem. Res. Toxicol. 2004, 17, 1064-1076.
- (11) Hard, T.; Kellenbach, E.; Boelens, R.; Maler, B. A.; Dahlman, K.; Freedman, L. P.; Carlstedt-Duke, J.; Yamamoto, K. R.; Gustafsson, J.-A.; Kaptein, R. Science 1990, 249, 157-160.
- (12) Freedman, L. P.; Luisi, B. F.; Korszun, Z. R.; Basavappa, R.; Sigler, P. B.; Yamamoto, K. R. *Nature* 1988, 334, 543–546.
- (13) Makino, Y.: Tanaka, H.: Dahlman-Wright, K.: Makino, I. Mol. Pharmacol. **1996**, *49*, 612–620.
- (14) GR-DBD was obtained as described in: Payne, J. C.; Rous, B. W.; Tenderholt, A. L.; Godwin, H. A. Biochemistry 2003, 42, 14214-14224.
- (15) ITC measurements were obtained under strictly anaerobic conditions on a MicroCal VP-ITC inside a custom glovebox, as described in ref 7. (16) Low, L. Y.; Hernandez, H.; Robinson, C. V.; O'Brien, R.; Grossmann,
- (10) Eow, E. T., Hernandez, H., Robinson, C. V., O Brien, R., Horssmann, J. G.; Ladbury, J. E.; Luisi, B. J. Mol. Biol. 2002, 319, 87–106.
 (17) Dhubhghaill, O. M. N.; Sadler, P. J. Struct. Bonding 1991, 78, 129–190.
 (18) Jiang, G.; Gong, Z.; Li, X.-F.; Cullen, W. R.; Le, X. C. Chem. Res. Toxicol. 2003, 16, 873–880.
 (19) Spuches, A. M.; Schenk, A. D.; Rous, B. W.; Godwin, H. A.; Wilcox, D. E. Marusentist in gramming the promotion.
- D. E. Manuscript in preparation. Net charge on the GR-DBD complexes in brackets accounts for the
- protonation state of the Cys thiols and charge on Zn^{2+} , As^{3+} , and $MeAs^{2}$ (21) NIST Standard Reference Database 46 (2003).

- (22) Finney, L. A.; O'Halloran, T. V. Science 2003, 300, 931–936.
 (23) Piatek, K.; Schwerdtle, T.; Hartwig, A.; Bal, W. Chem. Res. Toxicol. 2008, (23) 21, 600-606.
- JA802179P